ArticleBMC gastroenterology2025
The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimContrast-enhanced harmonic endoscopic ultrasound (CH-EUS) has promising potential in the diagnosis of pancreatic tumors, assessment of fibrosis, and prediction of chemotherapy efficacy. We hypothesize that radiation therapy might reduce variations in chemotherapeutic efficacy caused by fibrosis-induced blood flow disparities, as we explored the relationship between CH-EUS patterns and the efficacy of neoadjuvant chemoradiotherapy (NACRT) in resectable pancreatic cancer (PC).
methodsPatients with resectable PC who underwent CH-EUS followed by NACRT were retrospectively analyzed. The CH-EUS enhancement pattern was evaluated in the vascular and perfusion phases and classified according to vascularity: Group A, hypovascular in both phases; Group B, isovascular and hypovascular in the vascular and perfusion phases, respectively; and Group C, isovascular in both phases. The relationships between the CH-EUS vascular pattern and the histological response according to the Evans classification to NACRT, recurrence-free survival (RFS) and overall survival (OS) were evaluated.
resultsOf the 48 enrolled patients, 31, 11, and 6 were classified into Groups A, B, and C, respectively. There was no significant difference in histopathological differentiation (p = 0.314) or the efficacy of NACRT (p = 0.282) among the groups. In addition, there was no significant difference between the groups in terms of median RFS or OS, although it was longer than previously reported.
conclusionThe histopathological efficacy of NACRT for resectable PC did not differ significantly on the basis of enhancement pattern observed on CH-EUS. NACRT may provide additional therapeutic benefit independent of blood flow considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.